88 F. Supp. 3d 402
E.D. Pa.2015Background
- Cephalon (brand) settled Paragraph IV patent suits with four generic makers (Teva, Ranbaxy, Mylan, Barr) by granting date‑certain licenses and making ~ $300 million in side payments and related commercial deals.
- The suits involved Cephalon’s RE ’516 patent on modafinil (Provigil); plaintiffs allege the patent was weak/invalid and settlements were reverse‑payments to keep generics off market until 2012.
- Plaintiffs are Direct Purchasers, End Payors, the FTC, and Apotex; defendants moved for summary judgment arguing Actavis requires a threshold showing that payments were “large and unjustified.”
- The court framed the dispute under FTC v. Actavis and applied traditional rule‑of‑reason burden‑shifting to reverse‑payment cases, deciding where “large” and “unjustified” fit in that framework.
- The court found plaintiffs had presented sufficient evidence that payments were large (exceeding litigation cost savings and in some cases approximating expected generic profits) and that genuine disputes exist about whether defendants’ procompetitive explanations were pretextual.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Proper standard post‑Actavis | Apply ordinary rule of reason; plaintiff must show anticompetitive effects or market power | Actavis imposes a separate threshold: plaintiff must prove the payment was "large and unjustified" before rule of reason | Court: Actavis requires rule‑of‑reason; "large" is part of plaintiff's initial burden to show anticompetitive effect, but "unjustified" is addressed under defendants' burden to proffer justifications and plaintiff's rebuttal |
| Burden allocation on justifications | Defendants must justify payments after plaintiff shows anticompetitive effect | Plaintiffs’ view; defendants contend requiring them to justify creates presumption of illegality | Court: After plaintiff shows anticompetitive effect (including large payment), burden shifts to defendants to show procompetitive justification; plaintiff may then rebut |
| What counts as a "large" payment | A payment is large if it exceeds saved litigation costs or could induce a generic to forgo litigation/entry; total payment may be considered | Defendants: only the unexplained portion should count; compare to brand’s expected monopoly profits | Court: Consider the entire payment; benchmark includes litigation cost savings and whether payment could induce a generic to stay out (not limited to share of monopoly profits) |
| Sufficiency of evidence to rebut procompetitive justifications | Side agreements, inflated API prices, internal Cephalon documents and expert analyses show pretext and noncommercial motives | Defendants: payments were for litigation avoidance and fair value for services; fair‑market‑value proof required | Court: Plaintiffs produced sufficient direct and circumstantial evidence to create genuine disputes about pretext and necessity of side deals; summary judgment denied |
| Ranbaxy causation (antitrust injury) | Plaintiffs: internal Ranbaxy documents and conduct indicate it planned an at‑risk launch before settlement | Ranbaxy: it would not have launched at risk; settlement didn’t cause delay | Court: Conflicting evidence creates genuine factual dispute on causation; question for jury |
Key Cases Cited
- Federal Trade Commission v. Actavis, Inc., 133 S. Ct. 2223 (Sup. Ct. 2013) (rule‑of‑reason applies to reverse‑payment settlements; size and justification relevant)
- United States v. Brown Univ., 5 F.3d 658 (3d Cir. 1993) (describes plaintiff's initial burden under rule of reason)
- Chicago Bd. of Trade v. United States, 246 U.S. 231 (1918) (origin of the rule‑of‑reason analysis)
- Brunswick Corp. v. Pueblo Bowl‑O‑Mat, Inc., 429 U.S. 477 (1977) (defines antitrust injury and causation)
- Pa. Dental Ass'n v. Med. Serv. Ass'n of Pa., 745 F.2d 248 (3d Cir. 1984) (weighing of procompetitive versus anticompetitive effects under rule of reason)